Vectivbio AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Subsidiary
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.vectivbio.com
Clinical Trials
39
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials
Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- VectivBio AG
- Target Recruit Count
- 34
- Registration Number
- NCT06002555
- Locations
- 🇳🇱
ICON Clinical Research Unit, Groningen, Netherlands
Evaluation of Apraglutide on Gastric Emptying
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- VectivBio AG
- Target Recruit Count
- 42
- Registration Number
- NCT05995704
- Locations
- 🇳🇱
ICON Clinical Research Unit, Groningen, Netherlands
A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- VectivBio AG
- Target Recruit Count
- 16
- Registration Number
- NCT05706623
- Locations
- 🇩🇪
APEX, Münich, Germany
🇸🇰Summit Clinical Research, Bratislava, Slovakia
Proof-of-concept Trial of Apraglutide in GVHD
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- VectivBio AG
- Target Recruit Count
- 31
- Registration Number
- NCT05415410
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- VectivBio AG
- Target Recruit Count
- 158
- Registration Number
- NCT05018286
- Locations
- 🇯🇵
Yokohama Municipal Citizen's Hospital, Kanagawa, Japan
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Gastroenterology Group of Naples, Naples, Florida, United States
- Prev
- 1
- 2
- Next